A study partly funded by NHLBI shows that many people with asthma also have sleeping problems. The researchers found that insomnia is common among patients with poorly controlled asthma, which was also associated with depression and anxiety. The study appears in Chest.
NHLBI In The News
Filter News Mentions
A team of researchers partly funded by NHLBI believe they zeroed in on the biological mechanism behind ACDC Disease, a rare and painful genetic disorder. The finding, published in the Science Signaling, could lead to the first effective treatment for the disease and give researchers important insights into other vascular conditions such as atherosclerosis.
Researchers are reporting the identification of a gene that appears to decrease the risk of heart disease among women but not men. In the study, the researchers found that women who carried a gene variant called CSP1 had a 12 percent decreased risk for heart disease, but the same gene variant had no protective effect on men. The findings could help shed light on why heart disease affects women and men differently. The study, which appeared in Nature Communications, was partly funded by NHLBI.
Researchers partly funded by the NHLBI have found that fasting can have a great impact in acute lymphoblastic leukemia (ALL), the most common form of cancer in children. The study, published in Nature Medicine, shows that fasting not only inhibits the start but also reverses the leukemic progression of the cancer cells. The findings suggest new avenues for the development of leukemia treatments, according to the authors.
A study partly funded by the NHLBI shows that the age of the donor influences the quality of the induced pluripotent stem cells, the type of cell usually praised for its great therapeutic promise. The research, published in Nature Biotechnology, found that genetic mutations and the risk of abnormalities increased with the age of the cell donor. The findings highlight the importance of screening stem cells for harmful DNA mutations and should impact the development of the technology for reprograming these cells for therapeutic use, according to the researchers.
While chemotherapy and radiation therapy kill cancer cells, they can also damage blood-forming stem cells in the bone marrow and slow recovery in people with cancer. Now, in a pair of new studies conducted in mice, researchers are reporting the identification of two genetic factors that appear to control blood-forming stem cells and might lead to improvements in cancer therapy. In one study, scientists found that a gene called Grb10 appears to hinder the regenerative property of stem cells. In another study, scientists found that a protein called DKK1 boosted the ability of stem cells to regenerate. Together, these two studies could provide a way manipulate these factors to help regenerate stem cells and improve cancer therapy. The study on Grb10 appeared in Cell Reports and the study on DKK1 appeared in Nature Medicine. NHLBI partly funded both studies.
Researchers have developed a technique to see how drugs interact with individual cells, a finding that could help improve the drug development process, according to a study in Nature Chemical Biology. The National Heart, Lung, and Blood Institute supported the research, which used polarized microscopy technology to look at cells.
An NHLBI-funded study found that following the Dietary Approaches to Stop Hypertension, known as DASH diet, significantly lowers uric acid, which accumulates in the blood and cause gout. The findings, published in Arthritis & Rheumatology, showed the effect was almost equivalent to that achieved with drug treatment for gout.
Researchers have tested an experimental drug called SelG1 which shows promise in reducing the number of pain crises that those living with sickle cell disease experience, according to a study in the New England Journal of Medicine. The National Heart, Lung, and Blood Institute supported the research into the drug which is also known as crizanlizumab.
A gene called HOX9 has been shown to limit the ability of adult muscle stem cells to regenerate themselves, according to research appearing in Nature. The work, with funding from the National Heart, Lung, and Blood Institute, may be a therapeutic target for improving regenerative medicine.